Trial Profile
A study of dasatinib or nilotinib evaluating the therapeutic adherence in chronic myeloid leukemia patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2018
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 22 Jul 2018 New trial record
- 01 Jun 2018 Results published in the International Journal of Clinical Pharmacy